USPTO Says Arthrex Patent Do-Over Bid Could Paralyze Gov't
Arthrex's argument that the interim director of the U.S. Patent and Trademark Office cannot review Patent Trial and Appeal Board decisions misreads the law and would cause "paralysis" of many agencies...To view the full article, register now.
Already a subscriber? Click here to view full article